Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CE7R CAR-T cells |
| Synonyms | |
| Therapy Description |
CE7R CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD171 and containing CD28, CD3zeta, and TNFRSF9 (4-1BB) signaling domains and truncated EGFR, which potentially induces cytotoxicity in CD171-expressing tumors (PMID: 27390347). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CE7R CAR-T cells | CD171 CAR+ T Cells|CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T cells | CE7R CAR-T cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD171 and containing CD28, CD3zeta, and TNFRSF9 (4-1BB) signaling domains and truncated EGFR, which potentially induces cytotoxicity in CD171-expressing tumors (PMID: 27390347). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02311621 | Phase I | CE7R CAR-T cells | Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 | Active, not recruiting | USA | 0 |